Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volasertib + LDAC in elderly AML
NCT01721876Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Volasertib + Cytarabine with Placebo + Cytarabine (2 arms). Primary endpoint: Objective Response up to 52 months. Started Jan 2013; status: completed.
02
Drugs
volasertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01721876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721876.